| abstract |
The present invention provides a combination of protein-based biomarkers and biomarkers useful for assaying ovarian cancer status and endometrial cancer status in a patient. In particular, hepcidin is a biomarker for both ovarian and endometrial cancers, and a panel of biomarkers, including hepcidin, transthyretin and optionally other markers, may be used to display a subject sample in ovarian cancer or non-ovarian cancer. It turns out that it is useful to classify. Biomarkers can be detected by SELDI mass spectrometry. |